

Search

EN

Back

Absci Begins AI-Drug Trial, Analyst Lifts Price Target to $8

Back

Stock NewsThemesAbsci Begins AI-Drug Trial, Analyst Lifts Price Target to $8

Absci Begins AI-Drug Trial, Analyst Lifts Price Target to $8

Edgen Stock·Jan 03 2026, 17:40

Share to

Share to

Copy link

source:

[1] Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial (https://finance.yahoo.com/news/absci-corporat ...)

Recommend

Autolink Targets Next-Decade Vehicles With New PlatformJan 07 2026, 07:23 Louis Navellier Backs Nvidia, Palantir for 2026, Urges Exit from 'Junk Rally'Jan 07 2026, 07:12 Sanofi Targets Growth, Leveraging 40% Flu Vaccine Market ControlJan 07 2026, 07:09

Hot NewsJan 08 2026, 11:25

Top RetailersBarron's Signals Consumer Shift to Goods, Tipping 11 StocksJan 07 2026, 07:27

AI ChipAMD Sets February 3 Date for Q4 2025 Earnings ReportJan 07 2026, 07:26

AI ChipAutolink Taps AMD to Build Next-Gen Intelligent Vehicle PlatformsJan 07 2026, 07:24